Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Precision pharmacotherapy Clear all
Completed Phase 1 Interventional

Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy

NCT01495845
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack, Myocardial Infarction
Interventions
Pharmacogenomics testing for clopidogrel responsiveness
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 3, 2026, 7:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

NCT04106492
View directory record Official record
Conditions
Cancer
Interventions
SQ3370
Drug
Lead sponsor
Shasqi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Duarte, California • Palo Alto, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Not applicable Interventional

CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer

NCT02827370
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Behavioral Dietary Intervention
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Active, not recruiting Phase 4 Interventional

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rosuvastatin, Colchicine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Enrolling by invitation No phase listed Observational

Serial PET MPI in Patients Undergoing Cancer Treatment

NCT05913999
View directory record Official record
Conditions
Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease, Coronary Microvascular Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Pharmacotherapy Smoking Cessation Program

NCT04897607
View directory record Official record
Conditions
Smoking Cessation
Interventions
Standard Care, Precision pharmacotherapy
Behavioral
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Sep 3, 2026, 7:32 PM EDT
Terminated No phase listed Observational

ChemoFx® PRO - A Post-Market Data Collection Study

NCT00669422
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Neoplasms, Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 3, 2026, 7:32 PM EDT
Terminated No phase listed Observational

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

NCT05819827
View directory record Official record
Conditions
Bladder Cancer, Prostate Cancer, Testicular Cancer, Bladder Carcinoma, Genitourinary System Carcinoma, Malignant Testicular Neoplasm, Melanoma, Prostate Carcinoma, Sarcoma
Interventions
Blood and Tissue
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Active, not recruiting Phase 2 Interventional

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

NCT05767359
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

PRecision Interventions for SMoking in the SCCS

NCT03521141
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"
Drug · Genetic · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 3, 2026, 7:32 PM EDT
Recruiting No phase listed Observational

An External Control Arm Study in Non-Small Cell Lung Cancer

NCT07174388
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Monterey, California • Dover, Delaware • Milford, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Functional Precision Oncology for Metastatic Breast Cancer

NCT04450706
View directory record Official record
Conditions
HER2-negative Breast Cancer
Interventions
Precision Medicine, Physican Decision Making
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 3, 2026, 7:32 PM EDT
Terminated No phase listed Observational

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00288275
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
36
States / cities
Irvine, California • Los Angeles, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 3, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional Results available

Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy

NCT03223662
View directory record Official record
Conditions
Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms, Squamous Cell Carcinoma
Interventions
Chemoradiotherapy, Esophagectomy
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 3, 2026, 7:32 PM EDT
Suspended Phase 2 Interventional

Neuroinflammation in Patients With OCD

NCT04786548
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Celecoxib
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Not applicable Interventional Results available

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project

NCT03799341
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Metabolism Informed Smoking Treatment: The MIST RCT

NCT04590404
View directory record Official record
Conditions
Smoking
Interventions
Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach., Nicotine Replacement Therapy, Varenicline, Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)
Behavioral · Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

NCT03056599
View directory record Official record
Conditions
Soft Tissue Sarcoma Adult
Interventions
Multiple drug microinjection, CIVO device
Drug · Device
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Lake Success, New York • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver

NCT05182112
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Whole liver irradiation (WLI), Gemcitabine and Cisplatin
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 3, 2026, 7:32 PM EDT
Recruiting No phase listed Observational

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

NCT07677267
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 115 Years · Male only
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional

Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial

NCT00200096
View directory record Official record
Conditions
Cancer
Interventions
Acupuncture and questionnaires, placebo acupuncture
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 64 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Basking Ridge, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Sep 3, 2026, 7:32 PM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Recruiting Phase 2 Interventional

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

NCT02559778
View directory record Official record
Conditions
Neuroblastoma
Interventions
Ceritinib, dasatinib, sorafenib, vorinostat, DFMO
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Up to 22 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2035
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

NCT02764593
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Nivolumab, Cisplatin, Cetuximab, IMRT
Drug · Radiation
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
11
States / cities
Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 3, 2026, 7:32 PM EDT